Confluent Medical Technologies President and CEO Dean Schauer has assumed the role of Chairman in addition to his existing responsibilities. Schauer has served as CEO to Confluent for over a decade.
 
“I am honored by the trust our investors and employees have placed in me, allowing me the opportunity to take on the role of Chairman of the Board,” stated Schauer. “Over the past decade, I have witnessed firsthand our team’s unwavering commitment to innovation and excellence, which has been the driving force behind Confluent’s growth. Moving forward, we will continue to enhance our materials sciences capabilities, expand our customer partnerships, and increase our investments in supporting a seamless supply chain in support of our customers.  I am very excited to help guide our company into the next phase as we continue to deliver value to our partners and the patients they serve.”
 
“Under Dean’s leadership, Confluent has more than quadrupled revenue and has established itself as a pioneer, innovator, and trusted partner to OEMs globally,” said Kendall Garrison, Partner at TPG. “We are confident the company will continue to benefit from his expertise in this expanded role.”
 
This announcement marks an important step in Confluent’s continued efforts to align its leadership and operations with the growing needs of its clients. 
 
In March, Confluent welcomed Sandy Stojkovski and Brian Yoor, two seasoned executives with significant operational, financial, and industry expertise to its board. In 2022, TPG Capital invested in Confluent to fuel company growth.